Patents Assigned to Australian Biomedical Company Pty, Ltd.
-
Patent number: 10195226Abstract: A method of promoting recovery of cell viability of a damaged respiratory cell. The method includes a step of administering to the cell at least one pharmaceutically acceptable compound, which accelerates sialyglycoconjugate biosynthesis to restore sialylglycoconjugates on the surface of the respiratory cell. Also disclosed are a method and a pharmaceutical composition, both for treating a respiratory condition.Type: GrantFiled: May 8, 2015Date of Patent: February 5, 2019Assignee: Australian Biomedical Company Pty Ltd.Inventors: Betty Jin, Paul Arthur Jones, Ee Ling Seah, Wen Yang Wu, Peter James Jenkins
-
Patent number: 9040503Abstract: A method of promoting recovery of cell viability of a damaged respiratory cell. The method includes a step of administering to the cell at least one pharmaceutically acceptable compound, which accelerates sialyglycoconjugate biosynthesis to restore sialylglycoconjugates on the surface of the respiratory cell. Also disclosed are a method and a pharmaceutical composition, both for treating a respiratory condition.Type: GrantFiled: July 2, 2010Date of Patent: May 26, 2015Assignee: Australian Biomedical Company Pty Ltd.Inventors: Betty Jin, Paul Arthur Jones, Ee Ling Seah, Wen Yang Wu, Peter James Jenkins
-
Patent number: 8927565Abstract: Compositions including polymeric dialdehydes and compounds of where R1, R2, R7, R8, R9, and R10 may be the same or different and are selected from H, CH3, OH, OCH3, C2H5, OC2H5OCH2Ph, OCH2PhNO2, F or Cl; R3, R4, R5, R6 may be the same or different and are selected from H, CH3, OCH3, C2H5, OC2H5OCH2Ph, OCH2PhNO2, F or Cl, or R5 and R6 are the same or different and are selected from H, CH3, OCH3, C2H5, OC2H5OCH2Ph, OCH2PhNO2, F or Cl and R3 and R4 together are ?O, or R4 and R6 are the same or different and are selected from H, CH3, OCH3, C2H5, OC2H5OCH2Ph, OCH2PhNO2, F or Cl and R3 and R5 together form a double bond or are ?O, or R3 and R4, are the same or different and are selected from H, CH3, OCH3, C2H5, OC2H5OCH2Ph, OCH2PhNO2, F or Cl and R5 and R6 together are ?O; R11 and R12 together form ?CH2, or R11 and R12 may be the same or different and are independently selected from the group consisting of H, CH3, CH2CH3 and CH2CH2CH3; and X is selected from the group consisting of Cl, Br, SO4, I and R13COO,Type: GrantFiled: August 26, 2004Date of Patent: January 6, 2015Assignee: Australian Biomedical Company Pty. Ltd.Inventors: Betty Jin, Wen-Yang Wu
-
Patent number: 7968596Abstract: The present invention relates to application of compounds of formula (1) (Gibberellins) and their derivatives for the preparation of a pharmaceutical composition or medicaments for the treatment of diabetes, its complications and associated conditions, including obesity, micro and macro vascular diseases, nephropathy, neuropathy, eye diseases, diabetic ulcerations and the like. The method results the normalization of serum glucose level and other physiological conditions.Type: GrantFiled: August 24, 2006Date of Patent: June 28, 2011Assignee: Australian Biomedical Company Pty, Ltd.Inventors: Peter James Jenkins, Minnie Wu, David Shine Wu
-
Patent number: 7435756Abstract: The present invention relates to application of compounds of formula (1) (Gibberellins) and their derivatives for the preparation of a pharmaceutical composition or medicaments for the treatment of diabetes, its complications and associated conditions, including obesity, micro and macro vascular diseases, nephropathy, neuropathy, eye diseases, diabetic ulcerations and the like.Type: GrantFiled: February 12, 2004Date of Patent: October 14, 2008Assignee: Australian Biomedical Company Pty, Ltd.Inventors: Peter James Jenkins, Minnie Wu, David Shine Wu
-
Publication number: 20070197456Abstract: The present invention relates to application of compounds of formula (1) (Gibberellins) and their derivatives for the preparation of a pharmaceutical composition or medicaments for the treatment of diabetes, its complications and associated conditions, including obesity, micro and macro vascular diseases, nephropathy, neuropathy, eye diseases, diabetic ulcerations and the like. The method results the normalization of serum glucose level and other physiological conditions.Type: ApplicationFiled: August 24, 2006Publication date: August 23, 2007Applicant: AUSTRALIAN BIOMEDICAL COMPANY PTY, LTDInventors: Peter Jenkins, Minnie Wu, David Wu
-
Patent number: 6121317Abstract: Compounds of formula (1), (Gibberellins), and their pharmaceutically acceptable derivatives to promote ulcer-healing, healing of surgical wounds or open fractures and treatment of bronchitis or thrombophlebitis in animals including humans or cultivation of skin cell lines in vitro ##STR1## wherein A is COOR, where R is hydrogen, unsubstituted or substituted C.sub.1-20 alkyl, allyl, aryl, arylalkyl, amidine, NR.sup.4 R.sup.5 or an unsaturated or saturated ring containing one or more hetero-atoms selected from the group consisting of nitrogen, oxygen and sulfur; R.sup.4 and R.sup.5 may or may not be the same, are hydrogen, or C.sub.1-20 alkyl, allyl, aryl, arylalkyl or an unsaturated or saturated ring containing one or more hetero-atoms selected from the group consisting of nitrogen and sulfur; B is hydrogen, hydroxyl, mercaptan, or halogen, or A and B together form a --CO--O-- linkage; R.sup.1 is hydrogen, hydroxyl, mercaptan, halogen, amino, azido, NR.sup.4 R.sup.5, unsubstituted or substituted C.sub.Type: GrantFiled: November 9, 1998Date of Patent: September 19, 2000Assignee: Australian Biomedical Company Pty. Ltd.Inventors: Minne Wu, David Shine Wu